1. Imprecise risk estimation of chemotherapy-related cardiotoxicity in HER2-positive breast cancer using the recently reported societal risk tools

   • Osama Soliman
   • Aoife Lowery
   • On behalf of the Precision Cardio-Oncology Enterprise (P-CORE) Investigators

   Letter to the Editor 29 September 2021 Pages: 355 - 356

2. Systematic review and meta-analysis of febrile neutropenia risk with TCH(P) in HER2-positive breast cancer

   • Hannah Van Belle
   • Sara A. Hurvitz
   • Hans Wildiers

   Review 17 September 2021 Pages: 357 - 372

   

3. Methionine restriction exposes a targetable redox vulnerability of triple-negative breast cancer cells by inducing thioredoxin reductase

   • Dmitry Malin
   • Yoonkyu Lee
   • Vincent L. Cryns

   Preclinical study 22 September 2021 Pages: 373 - 387

   

4. Reduced menin expression leads to decreased ERα expression and is correlated with the occurrence of human luminal B-like and ER-negative breast cancer subtypes

   • Romain Teinturier
   • Razan Abou Ziki
   • Muriel Le Romancer

   Preclinical study Open access 24 September 2021 Pages: 389 - 401

   

5. Expression of neurotensin receptor-1 (NTS₁) in primary breast tumors, cellular distribution, and association with clinical and biological factors

   • Clément Morgat
   • Véronique Brouste
   • Elif Hindié

   Preclinical study 01 October 2021 Pages: 403 - 413

   

6. Metronomic chemotherapy (mCHT) in metastatic triple-negative breast cancer (TNBC) patients: results of the VICTOR-6 study

   • M. E. Cazzaniga
   • I. Vallini
   • The VICTOR Study Group

   Clinical trial Open access 21 September 2021 Pages: 415 - 424

   

7. A phase II study of sequential treatment with anthracycline and taxane followed by eribulin in patients with HER2-negative, locally advanced breast cancer (JBCRG-17)

   • Ippei Fukada
   • Yoshinori Ito
   • Norikazu Masuda

   Clinical trial Open access 23 September 2021 Pages: 425 - 434

   

8. Lack of cross-resistance between non-steroidal and steroidal aromatase inhibitors in breast cancer patients: the potential role of the adipokine leptin

   • Nazli Bahrami
   • Shakila Jabeen
   • Jürgen Geisler

   Clinical trial Open access 23 September 2021 Pages: 435 - 449

   

9. Impact of systemic adjuvant therapy and CYP2D6 activity on mammographic density in a cohort of tamoxifen-treated breast cancer patients

   • Linda Thorén
   • Mikael Eriksson
   • Sara Margolin

   Clinical trial Open access 27 September 2021 Pages: 451 - 462

   

10. Physical activity and Mediterranean diet as potential modulators of osteoprotegerin and soluble RANKL in gBRCA1/2 mutation carriers: results of the lifestyle intervention pilot study LIBRE-1

    • Leonie Neirich
    • Maryam Yahiaoui-Doktor
    • Sabine Grill

    Clinical trial Open access 27 September 2021 Pages: 463 - 475

    

11. Differential effects of CD20+ B cells and PD-L1+ immune cells on pathologic complete response and outcome: comparison between inflammatory breast cancer and locally advanced breast cancer patients

    • Hugo Arias-Pulido
    • Ashley Marie Cimino-Mathews
    • Steven Fiering

    Epidemiology 20 September 2021 Pages: 477 - 489

    

12. Population-based analysis of non-operative management and treatment patterns in older women with estrogen receptor-positive breast cancer

    • David Tejera
    • Mariam Rana
    • Stephanie M. Wong

    Epidemiology 20 September 2021 Pages: 491 - 501

    

13. Trend and survival benefit of contralateral prophylactic mastectomy among men with stage I–III unilateral breast cancer in the USA, 1998–2016

    • Yinlong Yang
    • Liangwei Pan
    • Zhiming Shao

    Epidemiology 23 September 2021 Pages: 503 - 515

    

14. Determinants of use of oral complementary-alternative medicine among women with early breast cancer: a focus on cancer-related fatigue

    • Pietro Lapidari
    • Nardjes Djehal
    • Antonio Di Meglio

    Epidemiology 24 September 2021 Pages: 517 - 529

    

15. Clinical trial representativeness and treatment intensity in a real-world sample of women with early stage breast cancer

    • Gabrielle B. Rocque
    • Nicole E. Caston
    • Risha Gidwani

    Epidemiology 29 September 2021 Pages: 531 - 540

    

16. Sleep medication use and risk of fractures in breast cancer survivors

    • Reina Haque
    • Rowan T. Chlebowski
    • LieHong Chen

    Epidemiology Open access 29 September 2021 Pages: 541 - 548

17. Racial/ethnic disparities in risk of breast cancer mortality by molecular subtype and stage at diagnosis

    • Nicole C. Lorona
    • Kathleen E. Malone
    • Christopher I. Li

    Epidemiology 15 October 2021 Pages: 549 - 558